BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23635777)

  • 1. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
    J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.
    Sarosiek KA; Cavallin LE; Bhatt S; Toomey NL; Natkunam Y; Blasini W; Gentles AJ; Ramos JC; Mesri EA; Lossos IS
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13069-74. PubMed ID: 20615981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
    Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
    J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
    Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
    Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.
    Mohanty S; Kumar A; Das P; Sahu SK; Choudhuri T
    Apoptosis; 2017 Sep; 22(9):1098-1115. PubMed ID: 28653223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
    Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES
    Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
    Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.
    Zhang YJ; Patel D; Nan Y; Fan S
    Antivir Ther; 2011; 16(5):657-66. PubMed ID: 21817187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma.
    Watanabe T; Nakamura S; Ono T; Ui S; Yagi S; Kagawa H; Watanabe H; Ohe T; Mashino T; Fujimuro M
    Biochem Biophys Res Commun; 2014 Aug; 451(1):93-100. PubMed ID: 25063029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
    Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
    Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
    Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
    Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
    Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
    Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7.
    Kim YJ; Kim Y; Kumar A; Kim CW; Toth Z; Cho NH; Lee HR
    PLoS Pathog; 2021 Jan; 17(1):e1009179. PubMed ID: 33471866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.